# Semax FAQ — Common Questions About the Research Literature

> Frequently asked questions about Semax: what it is, how BDNF induction works, what stroke research has found, the pharmacokinetic profile, regulatory status, safety data, and how it compares to Selank. Research context only.

The most common questions researchers and readers bring to this literature — answered directly, with citations.

## Frequently asked questions

**Q1: What is Semax and what does the research say about it?**

Semax (ACTH(4-7)PGP) is a synthetic heptapeptide — seven amino acids (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the 4-7 fragment of ACTH and extended with a C-terminal Pro-Gly-Pro tripeptide for stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it is registered as a pharmaceutical in Russia for ischemic stroke and cognitive impairment [15]. The Western research literature covers four main areas: neurotrophic factor induction (BDNF, NGF, NT-3), stroke neuroprotection via immunomodulatory gene programs, antidepressant-like and antistress effects in rodent models, and Alzheimer's-relevant amyloid-beta / copper-chelation mechanisms. The literature is active: new studies appeared in both 2024 and 2025.

**Q2: How does Semax increase BDNF in the brain?**

The mechanism isn't fully resolved at the receptor level, but the functional sequence is well documented. After intranasal delivery in rats, Semax at 50 microg/kg binds to specific ACTH-like receptor sites and induces rapid BDNF protein elevation in the basal forebrain — measurable within three hours and sustained over 24 hours [1]. At the mRNA level, hippocampal BDNF and NGF transcription increases within one hour [2]. In stroke models, the induction follows a temporal cascade: BDNF and TrkC mRNA at three hours, NT-3 and NGF at 24 hours, NGF again at 72 hours [3]. The effect is region-specific — not global — which matters for interpreting what 'BDNF upregulation' actually means in practice. Downstream CREB phosphorylation (enhanced by Semax in ischemic tissue [4]) is consistent with BDNF's known role in promoting synaptic plasticity via the TrkB/CREB axis.

**Q3: What animal studies have been done on Semax for stroke neuroprotection?**

The stroke literature is the deepest part of the Semax evidence base. Multiple independent research groups have used the tMCAO model (transient middle cerebral artery occlusion) in rats to document Semax's effects at both the protein and transcriptional level. Key studies: Sudarkina 2021 (JNK suppression + CREB enhancement at 24 hours, 100 microg/kg IP) [4]; Medvedeva 2014 (genome-wide transcriptional analysis, 96 genes altered at three hours) [5]; Filippenkov 2020 (394 differentially expressed genes at 24 hours, shift from inflammatory to neurotransmission programs) [6]; Filippenkov 2023 (131 differentially expressed genes, MHC class II downregulation) [7]. A separate photoinduced cortical ischemia model also showed reduced infarct volume and improved memory retention with intranasal Semax over six days [8].

**Q4: Is Semax an approved drug anywhere in the world?**

Yes — in the Russian Federation. Semax has been registered as a pharmaceutical since the 1990s for ischemic stroke and cognitive impairment, in an intranasal 0.1% formulation. The Russian registration safety profile documents no CNS depression, no cardiovascular toxicity, no drug dependence, and no withdrawal syndrome [15]. It is classified as a nootropic drug in the Russian pharmacopoeia. Semax has not received approval from the FDA (no IND or NDA has been filed), EMA, or equivalent agencies. In the United States, European Union, United Kingdom, and most other Western jurisdictions, its regulatory status is unresolved — it is not regulated as a pharmaceutical.

**Q5: What are the studied research doses and routes of administration?**

The two primary research doses are 50 microg/kg intranasal (neurotrophin, cognitive, and Alzheimer's-model studies) and 100 microg/kg intraperitoneal (stroke/ischemia models). A third dose — 60 nmol/kg daily IP, equivalent to approximately 53 microg/kg — was used in the 2024 chronic stress study [10]. The intranasal route is the clinically registered route; IP is the dominant route in rodent mechanistic studies and does not directly translate to human intranasal use. All doses described here are research doses studied in animal models — not clinical dosing information.

**Q6: How does Semax penetrate the blood-brain barrier after intranasal administration?**

A radiolabeled tracking study in rats administered 50 microg/kg intranasally and measured brain radioactivity at defined time points. Within two minutes, 0.093% of total administered radioactivity per gram was detectable in brain tissue, and approximately 80% of that signal represented intact, unmetabolized Semax [13]. By one hour, the Pro-Gly-Pro metabolite had become the predominant species in brain tissue. The PGP tripeptide was specifically engineered into the Semax sequence to extend resistance to peptidase degradation — without it, the parent ACTH(4-7) fragment would degrade before reaching the CNS [13]. Despite rapid conversion to PGP metabolite, biological effects persist for 20-24 hours, indicating receptor-initiated downstream signaling that outlasts the parent peptide.

**Q7: What is the difference between Semax and Pro-Gly-Pro?**

Pro-Gly-Pro (PGP) is the C-terminal tripeptide that was engineered into the Semax heptapeptide structure to confer peptidase resistance. It is not merely a tag — it is pharmacologically active on its own. Dmitrieva 2009 specifically compared the effects of intact Semax versus isolated PGP in a permanent MCAO model, finding that the neurotrophin gene activation observed with Semax was 'cortex-selective and distinct from non-specific PGP component activity' [3]. By one hour post-intranasal administration, PGP has become the predominant species in rat brain tissue [13]. The research literature therefore confronts a question not fully resolved: which pharmacological effects derive from intact Semax, which from PGP, and which from their sequential presence? The two compounds have overlapping but non-identical activity profiles.

**Q8: What does recent 2024-2025 research say about Semax and Alzheimer's disease?**

Two significant Alzheimer's-relevant findings appeared in the 2024-2025 period. First, Radchenko 2025 showed that intranasal Semax at 50 microg/kg every other day for one month in transgenic APPswe/PS1dE9 Alzheimer's-model mice reduced cortical amyloid plaque load by 2.8-fold at 7.5 months and 2.2-fold at 8.5 months, with preferential reduction of small newly-formed plaques [11]. Multiple cognitive behavioral tests (novel object recognition, Barnes maze) showed improvement. Second, a 2025 mechanistic study extended earlier in vitro copper-chelation work, confirming that Semax strips Cu2+ from amyloid-beta complexes, silences redox cycling, and reduces ROS-driven neurotoxicity — reinforcing the mechanism identified in Sciacca 2022 [9]. All of this data is preclinical; no human Alzheimer's trials of Semax have been published in Western journals.

**Q9: Does Semax have antidepressant-like effects in animal models?**

Yes, based on two independent rodent studies. Inozemtseva 2024 exposed male Sprague-Dawley rats to chronic unpredictable stress (a validated rodent model of depression) and treated them with Semax at 60 nmol/kg daily IP [10]. The peptide reversed anhedonia (restored sucrose preference), normalized body weight, reduced adrenal hypertrophy, and restored hippocampal BDNF levels — all four measures disrupted by chronic stress. Separately, Kamensky 2006 documented elevated striatal 5-HIAA (serotonin metabolite) following Semax administration in rodents, supporting a serotonergic component to its mood-modulating profile [16]. The BDNF restoration finding is mechanistically coherent with the compound's established BDNF-induction action: chronic stress depletes hippocampal BDNF, and Semax replenishes it.

**Q10: What is the safety profile of Semax based on available research?**

The available safety data comes primarily from the Russian regulatory record and animal toxicology studies. The Russian pharmacopoeial registration documents no CNS depression, no cardiovascular toxicity, no drug dependence, and no withdrawal syndrome [15]. No LD50 or dose-finding human safety study is available in indexed Western literature. In the rodent literature, no adverse behavioral or physiological effects are reported at the doses studied (50 microg/kg intranasal, 100 microg/kg IP), though this is not a formal toxicological safety profile. Standard caveats apply: animal-model safety data does not confirm human safety, and the absence of reported adverse effects in published studies reflects publication norms and study designs, not the absence of potential risks.

**Q11: How does Semax compare to Selank?**

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is another Russian-origin ACTH-derived regulatory heptapeptide, developed at the same institute as Semax. The research literature documents complementary but distinct activity profiles: Selank is more consistently characterized as anxiolytic and immunomodulatory in rodent studies, while Semax's literature centers on BDNF induction, stroke neuroprotection, and cognitive effects. Both compounds share the PGP C-terminal tripeptide, which may account for some overlapping anti-inflammatory properties. They are sometimes studied alongside each other in the Russian nootropic literature as a paired system. Neither is FDA-approved; both are registered in the Russian Federation.

**Q12: What does 'nootropic' mean in the Semax context?**

'Nootropic' is the pharmacological classification used for Semax in the Russian pharmacopoeia. The term broadly refers to substances studied for their potential to enhance cognitive functions — memory, learning, attention — without sedation or significant side effects. In Semax's case, the nootropic classification is supported by behavioral studies showing improved memory retention in cortical ischemia models [8], normalized stress-induced cognitive disruption in neonatal isolation models [14], improved performance on Barnes maze and novel object recognition in Alzheimer's-model mice [11], and the compound's well-documented BDNF-induction profile (BDNF is a key molecular correlate of synaptic plasticity and learning). Western regulatory agencies use different classification frameworks and have not evaluated Semax under any indication.

**Q13: Is Semax related to ACTH? What is the ACTH(4-7)PGP designation?**

Yes, structurally. ACTH (adrenocorticotropic hormone) is a 39-amino-acid pituitary hormone that regulates cortisol secretion. Its N-terminal region carries distinct bioactivity: the 4-10 fragment in particular has been identified as the portion responsible for cognitive and neuroprotective activity, independently of the adrenal effects mediated by the full ACTH molecule. Semax is derived from the 4-7 subfragment (four amino acids: Met-Glu-His-Phe), extended with Pro-Gly-Pro. The designation 'ACTH(4-7)PGP' identifies both the source fragment and the appended tripeptide. Semax does not significantly activate adrenal ACTH receptors at research doses — its biological activity profile diverges substantially from that of the full ACTH molecule.

**Q14: What is WADA's position on Semax?**

Semax is not explicitly named in the WADA Prohibited List, but it falls under category S0 (Non-Approved Substances) — a catch-all category covering any pharmacological substance not approved by a governmental regulatory authority for human therapeutic use. Any substance in the S0 category is prohibited in-competition for athletes subject to WADA rules, regardless of whether the substance is specifically named. The S0 classification reflects regulatory status (not FDA/EMA-approved outside Russia), not any specific evidence of performance enhancement in the WADA evidence review.

**Q15: Can I buy Semax outside Russia?**

Semax Reviews is an independent editorial publisher of research summaries. We do not sell any product, provide any product sourcing information, or affiliate with any vendor. We cannot answer questions about purchasing Semax. Regulatory status varies by jurisdiction — interested parties should consult applicable local law and, where relevant, a licensed clinician.

---

An interactive digest of peer-reviewed research — not a clinic, not a vendor, not medical advice.